Literature DB >> 6510461

Absorption of enprofylline from the gastrointestinal tract in healthy subjects.

E Lunell, K E Andersson, O Borgå, P O Fagerström, N Johannesson, G Kjellin, C G Persson, K Sjölund.   

Abstract

Enprofylline, a new potent bronchodilator xanthine drug, was given orally as an aqueous solution to 6 healthy subjects in single doses of 2, 4 and 6 mg/kg. The two lower doses produced plasma concentrations in the range 1-4 mg/l, i.e. in the assumed "therapeutic interval" according to previous animal studies. A high 24 h urine recovery of unchanged drug, with mean values for the three dose levels ranging from 85 to 91% of the given dose, indicated good absorption and little metabolism. The dose-corrected area under the plasma concentration-time curve rose with dose as the latter was increased from 2 to 6 mg/kg. This indicates that the elimination of enprofylline is capacity-limited at high doses. Double peaks in the plasma concentration-time curves at the higher dose levels suggested intermittent and delayed gastric emptying as a possible explanation. This hypothesis was confirmed by studies in 6 other healthy subjects, who received the drug solution by three different routes; by mouth, via a catheter in the duodenum, and rectally via a catheter in the colon. The corresponding time to peak values (mean +/- SEM) were 32.5 +/- 8.7, 13.3 +/- 2.5, and 157 +/- 23 min.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6510461     DOI: 10.1007/bf00542170

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Theory of the mean absorption time, an adjunct to conventional bioavailability studies.

Authors:  D J Cutler
Journal:  J Pharm Pharmacol       Date:  1978-08       Impact factor: 3.765

2.  Enprofylline, a principally new antiasthmatic xanthine.

Authors:  C G Persson; G Kjellin
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1981-10

3.  Enprofylline kinetics in healthy subjects after single doses.

Authors:  O Borgå; K E Andersson; L E Edholm; P O Fagerström; E Lunell; C G Persson
Journal:  Clin Pharmacol Ther       Date:  1983-12       Impact factor: 6.875

4.  Effects of enprofylline, a xanthine lacking adenosine receptor antagonism, in patients with chronic obstructive lung disease.

Authors:  E Lunell; N Svedmyr; K E Andersson; C G Persson
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

5.  Differentiation between bronchodilation and universal adenosine antagonism among xanthine derivatives.

Authors:  C G Persson; J A Karlsson; I Erjefält
Journal:  Life Sci       Date:  1982-06-21       Impact factor: 5.037

6.  Tolerance and some circulatory effects of intravenous and oral enprofylline in healthy volunteers.

Authors:  E Lunell; K E Andersson; C G Persson
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1983-09

7.  Tracheal relaxant and cardiostimulant actions of xanthines can be differentiated from diuretic and CNS-stimulant effects. Role of adenosine antagonism?

Authors:  C G Persson; I Erjefält; L E Edholm; J A Karlsson; C J Lamm
Journal:  Life Sci       Date:  1982-12-13       Impact factor: 5.037

8.  Intravenous administration of enprofylline to asthmatic patients.

Authors:  L C Laursen; N Johannesson; P O Fagerström; B Weeke
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Enprofylline--effects of a new bronchodilating xanthine derivative in asthmatic patients.

Authors:  L C Laursen; N Johannesson; A Dirksen; R Djurup; E P Munch; E Taudorf; B Weeke
Journal:  Allergy       Date:  1983-01       Impact factor: 13.146

10.  A novel bronchodilator xanthine apparently without adenosine receptor antagonism and tremorogenic effect.

Authors:  E Lunell; N Svedmyr; K E Andersson; C G Persson
Journal:  Eur J Respir Dis       Date:  1983-07
View more
  3 in total

Review 1.  Pharmacokinetics of rectal drug administration, Part II. Clinical applications of peripherally acting drugs, and conclusions.

Authors:  E J van Hoogdalem; A G de Boer; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

2.  The absorption of piretanide from the gastro-intestinal tract is site-dependent.

Authors:  D Brockmeier; H G Grigoleit; H Leonhardt
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Evaluation of the intestinal absorption of erythromycin in man: absolute bioavailability and comparison with enteric coated erythromycin.

Authors:  A A Somogyi; F Bochner; D Hetzel; D B Williams
Journal:  Pharm Res       Date:  1995-01       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.